source
- Kyntra Bio drops mid-stage prostate cancer ADC program after failing efficacy criteriaKyntra Bio announced in its third-quarter earnings release that it is terminating the phase 2 study of its CD46-targeting antibody-drug conjugate FG-3246 in metastatic castration-resistant prostate…
- Panelists say 2027 could be Europe’s breakout year for biotech investmentFierce Biotech hosted a panel during its London Life Sciences Week to debate whether Europe can boost its biopharma investment in 2027. The discussion came a day after venture capital firm Sofinno…